Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ALC logo ALC
Upturn stock ratingUpturn stock rating
ALC logo

Alcon AG (ALC)

Upturn stock ratingUpturn stock rating
$79.44
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: ALC (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

27 Analysts rated it

Well-followed company, solid analyst reports, reliable data for confident investing.

1 Year Target Price $97.6

1 Year Target Price $97.6

Analysts Price Target For last 52 week
$97.6 Target price
52w Low $78.11
Current$79.44
52w High $100.74

Analysis of Past Performance

Type Stock
Historic Profit -4.18%
Avg. Invested days 47
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 40.31B USD
Price to earnings Ratio 37.67
1Y Target Price 97.6
Price to earnings Ratio 37.67
1Y Target Price 97.6
Volume (30-day avg) 27
Beta 0.69
52 Weeks Range 78.11 - 100.74
Updated Date 08/28/2025
52 Weeks Range 78.11 - 100.74
Updated Date 08/28/2025
Dividends yield (FY) 0.41%
Basic EPS (TTM) 2.16

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-08-19
When -
Estimate 0.7194
Actual 0.76

Profitability

Profit Margin 10.7%
Operating Margin (TTM) 11.17%

Management Effectiveness

Return on Assets (TTM) 2.64%
Return on Equity (TTM) 4.98%

Valuation

Trailing PE 37.67
Forward PE 26.39
Enterprise Value 44026358176
Price to Sales(TTM) 4.02
Enterprise Value 44026358176
Price to Sales(TTM) 4.02
Enterprise Value to Revenue 4.39
Enterprise Value to EBITDA 16.04
Shares Outstanding 494400000
Shares Floating 493297488
Shares Outstanding 494400000
Shares Floating 493297488
Percent Insiders 0.13
Percent Institutions 69.48

ai summary icon Upturn AI SWOT

Alcon AG

stock logo

Company Overview

overview logo History and Background

Alcon was founded in 1945 as a small pharmacy in Fort Worth, Texas. In 1977, Nestlu00e9 acquired Alcon and significantly expanded its reach. Alcon became an independent company in 2019 after being spun off from Novartis.

business area logo Core Business Areas

  • Surgical: Focuses on surgical equipment and devices for cataract, refractive, and vitreoretinal surgery.
  • Vision Care: Offers contact lenses and lens care products.

leadership logo Leadership and Structure

David J. Endicott is the current CEO. Alcon operates with a global structure, divided into geographic regions with functional teams supporting each area.

Top Products and Market Share

overview logo Key Offerings

  • PanOptix IOL: A trifocal intraocular lens used in cataract surgery. Alcon claims to be the leading IOL provider. Competitors include Johnson & Johnson Vision, Bausch + Lomb.
  • Dailies Total1: A daily disposable contact lens. Competitors include Johnson & Johnson Acuvue, CooperVision.
  • Systane: Over-the-counter artificial tears for dry eye relief. Market share is significant in the OTC eye care market. Competitors include Refresh (Allergan), Blink (Abbott).

Market Dynamics

industry overview logo Industry Overview

The ophthalmic market is driven by an aging population, increasing prevalence of vision disorders, and technological advancements in surgical and vision care solutions.

Positioning

Alcon is a leading player in the ophthalmic market, with a strong portfolio of surgical and vision care products. Its competitive advantages include a global presence, established brand reputation, and continuous innovation.

Total Addressable Market (TAM)

The global ophthalmic market is estimated to be worth around $40 billion. Alcon is well-positioned to capture a significant share of this market.

Upturn SWOT Analysis

Strengths

  • Global brand recognition
  • Extensive product portfolio
  • Strong research and development capabilities
  • Established distribution network
  • Leading market positions in key segments

Weaknesses

  • Reliance on key products
  • Exposure to regulatory risks
  • Competition from established and emerging players
  • Impact of economic downturns on elective procedures

Opportunities

  • Expanding into emerging markets
  • Developing innovative products and technologies
  • Acquiring complementary businesses
  • Capitalizing on the growing demand for eye care solutions
  • Strategic partnerships and collaborations

Threats

  • Intense competition
  • Pricing pressures
  • Changes in reimbursement policies
  • Product liability claims
  • Economic instability

Competitors and Market Share

competitor logo Key Competitors

  • JNJ
  • BSY
  • COO

Competitive Landscape

Alcon faces intense competition from established players such as Johnson & Johnson and Bausch + Lomb. Alcon's competitive advantages include its broad product portfolio and global presence.

Major Acquisitions

Ivantis, Inc.

  • Year: 2022
  • Acquisition Price (USD millions): 475
  • Strategic Rationale: Expanded Alcon's glaucoma portfolio with Ivantis's Hydrus Microstent.

Growth Trajectory and Initiatives

Historical Growth: Alcon has demonstrated moderate revenue growth in recent years, driven by strong performance in its surgical and vision care segments.

Future Projections: Analyst estimates project continued revenue growth in the mid-single digits, driven by new product launches and expansion into emerging markets.

Recent Initiatives: Recent initiatives include the launch of new contact lens and IOL products, as well as strategic acquisitions to expand its product portfolio and geographic reach.

Summary

Alcon is a strong player in the ophthalmic market with a diverse portfolio and global presence. The company's growth is driven by innovative products and strategic acquisitions. Alcon needs to be wary of competition from Johnson & Johnson and Bausch + Lomb, as well as potential regulatory changes. The lack of dividend payout, although not necessarily critical can make them less desirable against their counterparts.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Alcon Investor Relations
  • Market Research Reports
  • Analyst Estimates

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly, and past performance is not indicative of future results.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Alcon AG

Exchange NYSE
Headquaters -
IPO Launch date 2019-04-09
CEO & Director Mr. David J. Endicott
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 25000
Full time employees 25000

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. It operates through two segments, Surgical and Vision Care. The company offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, grieshaber, MIVS instruments, scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.